Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation & Cellular Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GM-CSF drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GM-CSF (CSF2) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (Native Glycosylation). |
View GM-CSF Products |
| Gene Delivery | GM-CSF Promise-ORF Full-length ORF for stable cell lines. |
View GM-CSF Products |
| Receptor Alpha | CSF2RA (CD116) ECD-Fc Fusion High affinity extracellular domain for ligand binding and competition assays. |
View CSF2RA Products |
| Common Beta Chain | CSF2RB (CD131) Lentivirus Full-length ORF for stable cell line generation and heterodimeric receptor studies. |
View CSF2RB Products |
| Benchmark Ab | Anti-GM-CSF (Lenzilumab/Namilumab/Otilimab/Mavrilimumab Biosimilar Sequences) Recombinant positive control / reference standard. |
View GM-CSF Products |
| Validator | GM-CSF siRNA Set For knockdown verification and specificity controls. |
View GM-CSF Products |
| Related Target A | CSF2RA Cognate receptor alpha subunit for binding assays. |
View CSF2RA Products |
| Related Target B | IL-6 Synergistic inflammatory cytokine for CRS profiling. |
View IL-6 Products |
| Related Target C | CSF3 (G-CSF) Granulocyte colony-stimulating factor, distinct myeloid differentiation profile, comparative immunology. |
View CSF3 Products |
| Related Target D | IL-3 Shared CSF2RB signaling, hematopoietic synergy, off-target screening reference. |
View IL-3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity, sequence-verified for preclinical translation accuracy |
| Subfamily counter screening | Homolog panel proteins strictly verified by mass spec for selectivity discrimination |
| Receptor Heterodimer Binding (CSF2RA/CSF2RB) | Bifunctional assay support with CSF2RA ECD-Fc and CSF2RB full-length lentivirus for complex validation |
| Neutralizing Antibody Validation | High-activity GM-CSF protein with guaranteed endotoxin control (<1 EU/µg) for sensitive cell proliferation assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live GM-CSF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Neutralizing Antibody Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for GM-CSF therapeutics is intensifying, with a fundamental paradigm shift from historical use as a hematopoietic growth factor to contemporary targeting as a master pro-inflammatory cytokine in autoimmune diseases and cytokine release syndromes. As first-generation therapies (anti-GM-CSF antibodies, CSF2RA blockade) advance through Phase III for Rheumatoid Arthritis and CAR-T induced Cytokine Release Syndrome (CRS), the next wave of R&D is targeting precision immune modulation, neuro-inflammation, and epitope-specific neutralization. The R&D focus has shifted toward high-fidelity species-cross reactive validation to support preclinical toxicology, given the limited homology between human and rodent GM-CSF.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-GM-CSF Monoclonal Antibody | Humanigen (Lenzilumab), Roivant, Roche (Otilimab), Kinevent (Namilumab), I-Mab (TJM2) | CRS, Rheumatoid Arthritis, Psoriatic Arthritis, COVID-19 CRS | Neutralization Assay (Need high-purity active Cytokine <1EU/µg) |
| Receptor Antagonist / CSF2RA Inhibition | Kiniksa (Mavrilimumab), Emerging biotech pipelines | Giant Cell Arteritis, Cytokine Storm, Neuroinflammation, ALS | Receptor Binding Assay (Need CSF2RA/CSF2RB proteins) |
| Bispecific | Various Early-Stage | Severe Asthma / COPD | Heterodimer Validation (Need Cross-reactive Abs) |
| GM-CSF Fusion / CAR-T Armor | Academic/Biotech partnerships (Bioskier) | Solid Tumor CAR-T enhancement, Vaccine adjuvants | Receptor Binding (Need CSF2RA ECD-Fc for affinity ranking) |
| Decoy/Antagonist Proteins | Preclinical (Fusion proteins) | ARDS, Sepsis, Multiple Sclerosis | Heterodimer stability assays (CSF2RA/CSF2RB complex validation) |
Key Assay Strategies for GM-CSF Drug Development
- Affinity & Neutralization: Ultra-high sensitivity SPR/BLI kinetics; TF-1 cell proliferation inhibition assays for functional validation.
- Cross-species Reactivity: Parallel comparison of human, cyno, and mouse ortholog binding (ELISA/SPR) to select appropriate toxicology models.
- Epitope Competition & Receptor Blocking: Precise binding at the CSF2RA/CSF2RB interface using competitive ELISA with high-quality recombinant receptor proteins.
TarMart Solution Summary
TarMart provides HEK293-expressed, high-purity (>95%) GM-CSF recombinant protein with native glycosylation and low endotoxin (<1EU/µg). Our toolkit includes receptor complex proteins (CSF2RA, CSF2RB), clinical benchmark antibodies (biosimilars of Lenzilumab, Namilumab, Otilimab, Mavrilimumab), siRNA validation sets, and ortholog proteins for cross-species studies. This comprehensive ecosystem enables robust drug discovery from hit identification to preclinical validation.